Does ELRANATAMAB-BCMM Cause Second primary malignancy? 7 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Second primary malignancy have been filed in association with ELRANATAMAB-BCMM. This represents 1.2% of all adverse event reports for ELRANATAMAB-BCMM.
7
Reports of Second primary malignancy with ELRANATAMAB-BCMM
1.2%
of all ELRANATAMAB-BCMM reports
1
Deaths
2
Hospitalizations
How Dangerous Is Second primary malignancy From ELRANATAMAB-BCMM?
Of the 7 reports, 1 (14.3%) resulted in death, 2 (28.6%) required hospitalization, and 2 (28.6%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ELRANATAMAB-BCMM. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does ELRANATAMAB-BCMM Cause?
Cytokine release syndrome (115)
Death (51)
Pyrexia (46)
Fatigue (31)
Neoplasm progression (31)
Cytomegalovirus infection reactivation (29)
Malignant neoplasm progression (27)
Off label use (27)
Immune effector cell-associated neurotoxicity syndrome (26)
Infection (25)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which ELRANATAMAB-BCMM Alternatives Have Lower Second primary malignancy Risk?
ELRANATAMAB-BCMM vs ELTROMBOPAG
ELRANATAMAB-BCMM vs ELTROMBOPAG OLAMINE
ELRANATAMAB-BCMM vs ELUXADOLINE
ELRANATAMAB-BCMM vs ELVITEGRAVIR
ELRANATAMAB-BCMM vs EMAPALUMAB